The DOI matches its Crossref record; 239 of the 239 references it cites were found in a registry or an index.
Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy
Open accessAbstract
OBJECTIVES: To investigate the screening performance of measuring blood pressure and other variables in identifying those who will develop, or die from, ischaemic heart disease and stroke. To quantify by how much drugs that lower blood pressure will reduce the risk of ischaemic heart disease and stroke in those designated 'screen positive'. DATA SOURCES: MEDLINE, Cochrane collaboration and Web of Science databases; Stroke registries; Health Survey for England; Office of National Statistics; BUPA (British United Provident Association) study. REVIEW METHODS: Relevant cohort studies and randomised trials were identified and analysed. Statistical analysis was used to determine drug efficacy and adverse effects. RESULTS: Lowering blood pressure by 5 mmHg diastolic reduces the risk of stroke by an estimated 34% and ischaemic heart disease by 21% from any pre-treatment level; there is no threshold. These estimates, from cohort studies, have been corroborated by the results of randomised trials in persons with high, average and below average levels of blood pressure. In spite of its importance in causing cardiovascular disease blood pressure is a poor predictor of cardiovascular events. Its poor screening performance is illustrated by the findings that in the largest cohort study, persons in the top 10% of the distribution of systolic blood pressure experienced only 21% of all ischaemic heart disease events and 28% of all strokes at a given age. Combining several reversible risk factors adds little to the screening performance of blood pressure alone; for example the 25% of men aged 5564 at highest computed risk (> or =1%) experience only 46% of all ischaemic heart disease events. The main methods of screening should be to identify all persons with a history of cardiovascular disease events (for example identifying patients at the time of hospital discharge following a first myocardial infarction detects 50% of all heart disease deaths in a population at a false positive rate of 12%), and to use a person's age. Identifying everyone with a history of myocardial infarction or stroke in a population and everyone aged 55 or more would include 98% of all deaths from ischaemic heart disease and stroke. The five main categories of blood pressure lowering drugs, thiazides, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II receptor antagonists and calcium channel blockers, significantly reduce blood pressure from all pre-treatment levels though the extent of the blood pressure reduction increased with pre-treatment blood pressure. The reductions were similar at standard dose for the five categories; average reduction was 9.1 systolic and 5 diastolic. The effect of combinations of two drugs on blood pressure was additive. No effect of age was apparent, given blood pressure. There were no serious metabolic consequences of using these drugs in standard dose. CONCLUSIONS: The evidence presented indicates that three drugs in combination may reduce stroke by about two-thirds and ischaemic heart disease by half. The report suggests that the term hypertension should be avoided because it is not a disease and it implies another category (normotensives) who would not benefit from lowering blood pressure. Blood pressure reduction using combinations of safe, well-established drugs is effective in preventing cardiovascular events. It is therefore suggested that such preventive therapy be considered more widely in people who by virtue of existing disease or simply age are at risk of a heart attack or stroke regardless of initial blood pressure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–239 of 239
Papademetriou, V., Price, M., Johnson, E., Smith, M. A., & Freis, E. D. (1984) · The American Journal of Cardiology · doi:10.1016/s0002-9149(84)80136-8 · Cited by 18
Cardiovascular responses to verapamil and propranolol in hypertensive patients.
McInnes, G. T., Findlay, I. N., Murray, G. D., Cleland, J. G. F., & Dargie, H. J. (1985) · PubMed · Cited by 17
Combination of verapamil and beta blockers in systemic hypertension
Dargie, H., Cleland, J. G. F., Findlay, I. N., Murray, G. D., & McInnes, G. T. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90812-x · Cited by 17
McCarron, D. A. (1991) · Clinical Cardiology · doi:10.1002/clc.4960140908 · Cited by 17
Thürig, C., Böhlen, L., Schneider, M., de Courten, M., Shaw, S., Weidmann, P. U., & Riesen, W. (1995) · European Journal of Clinical Pharmacology · doi:10.1007/bf00192353 · Cited by 17
Low-dose bisoprolol/hydrochlorothiazide: an option in first-line, antihypertensive treatment.
Zachariah, P. K., Messerli, F. H., & Mroczek, W. J. (1993) · PubMed · Cited by 16
Schmitz, A., Pedersen, M. M., & Mogensen, C. E. (1990) · American Journal of Hypertension · doi:10.1093/ajh/3.8.611 · Cited by 16
Rake, E., Breeze, E., & Fletcher, A. (2001) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001283 · Cited by 15
Effectiveness of once-daily monotherapy with a new nifedipine sustained release calcium antagonist
Carr, A. A., Bottini, P. B., Feig, P. U., Prisant, L. M., Mulligan, S., Devane, J. G., Fisher, L. D., Rhoades, R. B., & Carthy, E. P. M. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)90015-q · Cited by 15
Kahan, T., & Eliasson, K. (1999) · American Journal of Hypertension · doi:10.1016/s0895-7061(99)00155-7 · Cited by 15
Clinical Epidemiology of Stroke
Thompson, D. W., & Furlan, A. J. (1997) · Neurosurgery Clinics of North America · doi:10.1016/s1042-3680(18)30329-2 · Cited by 14
Pool, P. E., Applegate, W. B., Woehler, T. R., Sandall, P. G., & Cady, W. J. (1993) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1993.tb04312.x · Cited by 14
Behavioral and physiological effects of a beta blocker and relaxation therapy on mild hypertensives.
Adsett, C. A., Bellissimo, A., Mitchell, A., Wilczynski, N. L., & Haynes, R. B. (1989) · Psychosomatic Medicine · doi:10.1097/00006842-198909000-00004 · Cited by 14
Porcellati, C., Verdecchia, P., Gatteschi, C., Benemio, G., Guerrieri, M., Boldrini, F., & Pollavini, G. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562543 · Cited by 13
Antihypertensive Profiles with Ascending Dose Combinations of Ramipril and Felodipine Er
Scholze, J., Bauer, B., & Massaro, J. M. (1999) · Clinical and Experimental Hypertension · doi:10.3109/10641969909070859 · Cited by 13
Pordy, R. C. (2008) · Cardiology · doi:10.1159/000176704 · Cited by 13
Tonkin, A., Wing, L. M. H., Russell, A. E., West, M., Bune, A. J. C., Morris, M. J., Cain, M. D., & Chalmers, J. P. (1990) · Journal of Hypertension · doi:10.1097/00004872-199011000-00007 · Cited by 13
Jafar, T. H., Schmid, C. H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., Maschio, G., Brenner, B. M., Kamper, A., & Zucchelli, P. (2001) · eCommons - AKU (Aga Khan University) · Cited by 13
Jäättelä, A., Baandrup, S., Jj, H., & Westergren, G. (1990) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1990.tb03499.x · Cited by 12
Antihypertensive Effects of a New Sustained‐Release Formulation of Nifedipine
Zachariah, P. K., Schwartz, G. L., Sheps, S. G., SCHIRGER, A., Carlson, C. A., & Moore, A. G. (1990) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1990.tb03588.x · Cited by 11
Soro, S., Cocca, A., Pasanisi, F., Tommaselli, A. P., SIMONE, G. D., Costantino, G., & Ferrara, L. A. (1990) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1990.tb03451.x · Cited by 11
An assessment of lacidipine and atenolol in mild to moderate hypertension.
Lyons, D. J., Fowler, G., Webster, J., Hall, S. T., & Petrie, J. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04237.x · Cited by 10
Nicardipine sustained release in hypertension.
Webster, J., Petrie, J., Jeffers, T. A., Roy‐Chaudhury, P., Crichton, W., Witte, K. K., Jamieson, M. J., MacDonald, F., Beard, M. M., Dow, R. J., et al. (1991) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1991.tb03927.x · Cited by 10
The 24-Hour Efficacy of a New Once-Daily Formulation of Nifedipine
Zanchetti, A. (1994) · Drugs · doi:10.2165/00003495-199400481-00007 · Cited by 10
Moser, M., Abraham, P. A., Bennett, W. M., et al. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.36 · Cited by 10
Houston, M. C., Burger, C., Hays, J. T., Nadeau, J., Swift, L. L., Bradley, C., & Olafsson, L. (1990) · American Heart Journal · doi:10.1016/0002-8703(90)90175-w · Cited by 10
Lacidipine, hydrochlorothiazide and their combination in systolic hypertension in the elderly
Wing, L. M. H., Arnolda, L., Harvey, P., Upton, J. M., Molloy, D., Bune, A. J. C., & Chalmers, J. P. (1997) · Journal of Hypertension · doi:10.1097/00004872-199715120-00019 · Cited by 10
Maclean, D., Mitchell, E., Lewis, R., Irvine, N., McLay, J., McEwen, J., Coulson, R., Slater, N., Fitzsimons, T. J., & McDevitt, D. (1990) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1990.tb03664.x · Cited by 9
Long-Acting and Short-Acting Diuretics in Mild Essential Hypertension
Wing, L. M. H., West, M., Graham, J. R., & Chalmers, J. P. (1982) · Clinical and Experimental Hypertension · doi:10.3109/10641968209060800 · Cited by 9
Treatment of the hyperventilation syndrome with bisoprolol: A placebo-controlled clinical trial
van de Ven, L. L. M., Mouthaan, B. J., & Hoes, M. J. A. J. M. (1995) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(95)00508-0 · Cited by 9
Neutel, J. M., Buckalew, V. M., Chrysant, S. G., Mroczek, W. J., Ruff, D. A., & Weber, M. A. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70467-9 · Cited by 9
Petersen, J. R., Drabaek, H., Gleerup, G., Mehlsen, J., Petersen, L. J., & Winther, K. (1996) · Angiology · doi:10.1177/000331979604700303 · Cited by 8
Durel, L. A., Hayashi, P. J., Weidler, D. J., & Schneiderman, N. (1992) · The Journal of Clinical Pharmacology · doi:10.1177/009127009203200613 · Cited by 7
Meeves, S. G., & Park, G. D. (1994) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1994.tb03991.x · Cited by 6
Dose-Response Relationship of Ramipril in Patients with Mild-to-Moderate Hypertension
Schnaper, H. W. (1991) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199100182-00027 · Cited by 5
Bonaduce, D., Canonico, V., Petretta, M., Forgione, L., Ianniciello, A., Cavallaro, V., Bertocchi, F., & Rengo, F. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050344 · Cited by 5
Antihypertensive effect of slow-release nicardipine. A placebo-controlled cross-over study
Salvetti, A., Cardellino, G., Pesenti, M., Caiazza, A., Ghisoni, F., Prato, C. D., Innocenti, P., Ponzanelli, F., Errico, M., Freda, M., et al. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00558066 · Cited by 5
Kimura, S., DeQuattro, V. L., Hernandez, P., & Lee, D. D.-P. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)91216-7 · Cited by 3
D, K. H. M., Mori, T., Tanaka, H., Takada, Y., Matsunaga, A., Kiyonaga, A., Shindo, M., Sasaki, J., & Arakawa, K. (1992) · Cardiovascular Drugs and Therapy · doi:10.1007/bf00050921 · Cited by 2
Cited by
Law, M. R., Morris, J. K., & Wald, N. J. (2009) · BMJ · doi:10.1136/bmj.b1665 · Cited by 2,775
“As the reduction in blood pressure was not reported in most trials of people with a history of CHD, we estimated the average reduction from the average blood pressure before treatment and the average drug dose (as a multiple of standard dose”
BackgroundSelf-citationA strategy to reduce cardiovascular disease by more than 80%
Wald, N. J., & Law, M. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1419 · Cited by 1,568
Self-citationA Framework for Public Health Action: The Health Impact Pyramid
Frieden, T. R. (2010) · American Journal of Public Health · doi:10.2105/ajph.2009.185652 · Cited by 1,535
Fragala, M. S., Cadore, E. L., Dorgo, S., Izquierdo, M., Kraemer, W. J., Peterson, M. D., & Ryan, E. D. (2019) · Journal of Strength and Conditioning Research · doi:10.1519/jsc.0000000000003230 · Cited by 1,290
Law, M. R., Wald, N. J., Morris, J. K., & Jordan, R. E. (2003) · BMJ · doi:10.1136/bmj.326.7404.1427 · Cited by 1,232
Self-citation
Metadata
- Authors
- Law, M., Wald, N., & Morris, J.
- Venue
- Health Technology Assessment
- Published
- 2003-11
- Volume
- 7
- Issue
- 31
- Pages
- 1-94
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2107993459
- Cited by
- 327
- References
- 239
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.